New England Discovery Partners, LLC

Biotech · Private

Small molecule antivirals targeting oligosaccharyltransferase (OST) for flavivirus infection treatment

nedp.com →
Grants
$818K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Small molecule inhibitors of group II introns for treatment of fungal infections$224,015
Federal grantDepartment of Health and Human Services · Phase I · Targeting STT3A and STT3B to Block Flavivirus Replication$298,652
Federal grantDepartment of Health and Human Services · Phase I · Targeting STT3A and STT3B to Block Flavivirus Replication$295,298
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1243DEKK-TEC, INC.——
1244QX Therapeutics, Inc.——
1245DIGITAL PROTEOMICS LLC——
1246New England Discovery Partners, LLC——
1247TARGUT BIOTECHNOLOGIES INC.——
1248SignalRx Pharmaceuticals Inc.—$250K
1249Tooth Bank, LLC—$200K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.